Calix valuation turns on Bacchus Marsh revenue from Green360 tolling

Calix (ASX: CXL) has reached an important point because its valuation now rests less on distant decarbonisation promise and more on whether its existing assets can convert into repeatable revenue.

The clearest recent example was the 23 March Green360 toll processing agreement, which allows Calix to process up to 30,000 tonnes a year of calcined clay at Bacchus Marsh on a cost-plus basis, with first revenue expected in FY26 and no new capital required from Calix. That mattered because it showed the company can monetise idle or underused infrastructure now, not just talk about future licensing royalties.

That announcement followed a stronger half-year result in February and a restructuring of the lithium Mid-Stream project with PLS that removed a funding burden and brought in $11.4m in cash. Taken together, these updates explain why the stock has attracted fresh attention over the past six months.

Over the last 12 months, the shares have traded as a high-expectations industrial technology name, rising on strategic milestones and then pulling back when investors focused on capital intensity, project timing and cash burn. The biggest positive inflection came from a cluster of announcements rather than one earnings beat: the Rio Tinto joint development agreement for Zesty in November, the new U.S. water treatment contract in December, the completed lithium Mid-Stream Demonstration Plant later that month, and then the February-March sequence of better revenue, lower costs, the PLS restructure and Green360 tolling.

What are the Best ASX Stocks to invest in right now?

Check our buy/sell tips

Revenue quality matters more here

Among those, the Green360 announcement generated the clearest near-term re-rating logic because it tied an existing commercial calciner to an immediate revenue stream.

Unlike a memorandum of understanding or a study award, this was an operating contract with defined throughput potential. In our view, that is exactly the sort of evidence investors needed after a period when Calix had too many moving pieces and not enough visible monetisation.

Calix is an environmental technology company focused on industrial decarbonisation and sustainability.

Its core capability is a patented indirect heating calciner platform that can process minerals and industrial materials with lower emissions and, in some applications, separate carbon dioxide more efficiently than conventional methods. The business model is split three ways: direct product and services sales through the Magnesia business, paid engineering and testing work through its technology centre and demonstration assets, and a longer-term licensing model in target markets such as cement, lime, alumina and lithium.

This distinction matters. Magnesia is the cash-generating division today.

The asset base is the real story

It sells magnesium hydroxide water treatment products and services, with operations supported by the Myrtle Springs magnesium carbonate mine and manufacturing assets at Bacchus Marsh, Caloundra, Nerang and through IER facilities in the United States. In 1H FY26, Magnesia revenue was $15.8m, up 48%, helping total product and services revenue rise 21% to $16.3m. Gross profit increased 37% and operating costs fell 30%.

That is the kind of progress quality-growth investors want to see. It is not just top-line growth, but better commercial discipline. We think this is the most important structural development of the last six months because it improves the credibility of management’s stated path toward cash flow neutrality in CY2026.

The newer contract wins reinforce that point. The December U.S. water treatment agreement is expected to add up to $10m a year in product and services revenue, with sales ramping from the March quarter of calendar 2026. The Green360 tolling contract adds another revenue line using existing Bacchus Marsh capacity. These are not transformative individually, but they are repeatable and relatively tangible.

The market is also watching Calix because of its portfolio of strategic decarbonisation projects. Leilac targets carbon capture in lime and cement. Zesty targets green iron through a demonstration plant in Kwinana. ZEAL is focused on low-emissions alumina with Norsk Hydro. The lithium Mid-Stream technology aims to improve processing economics and emissions.

These projects give Calix multiple shots on goal, but they are not all equal from a valuation standpoint. The structural story is that one core technology platform may be licensed across several large industrial markets.

The short-term reality is that several of these programs are still at pilot, demonstration, feasibility or pre-Front End Engineering and Design (pre-FEED) stage. That means timing is uncertain and funding remains a genuine overhang.

The February restructuring with PLS was important because it clarified this. PLS agreed to acquire Calix’s ownership in the Mid-Stream demonstration plant joint venture for $11.4m cash, take full ownership and fund operations, while Calix keeps the intellectual property and will provide paid technical support.

The asset base is the real story

In our opinion, that was a smart move. It recycles capital, cuts direct project risk and brings the lithium opportunity closer to Calix’s preferred capital-light licensing model.

The single most important driver of the current valuation is whether Calix can prove that its platform can generate recurring, lower-risk revenue before the large licensing royalties arrive.

If Magnesia continues to grow, tolling revenue starts on schedule, engineering and technical services build, and partner-funded projects advance without heavy balance-sheet strain, the stock can strengthen further. If those pieces stall, investors will once again focus on cash consumption and deferred commercialisation.

For the shares to move materially higher, we believe several technical conditions need to be met. First, the new U.S. customer must ramp in line with expectations.

Second, Green360 throughput needs to convert into actual FY26 revenue and gross profit, not just contracted capacity. Third, the $11.4m PLS cash payment should land after final documents complete, strengthening liquidity. Fourth, Zesty needs to move closer to Final Investment Decision (FID) in 2026 with matched funding secured, building on the first ARENA milestone and the initial $2m payment.

The final call from here

On the negative side, the stock would weaken materially if Zesty funding slips, if Leilac-2 remains delayed on permitting and financing, or if the path to cash flow neutrality starts to look unrealistic.

Calix now has more evidence of commercial traction, more partner support and a cleaner capital-light pathway than it did a few months ago. In our view, the stock looks attractive for retail investors who can tolerate volatility and focus on the next 12 to 24 months. The key is simple: if Calix keeps turning technical credibility into paid revenue, the shares should have further to run.